HTG2014-Section-Header-publications

Categories

Filter by Topics

AACR2023 ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling B-accute lyphoblastic seukemia B-ALL Biology of neoplasia Biomarkers Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN Blood bone Brain Breast Cancer CAR T cell therapy Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs clinical trial Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity Efficacy EHE cancer EMT Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins IOA- 244 IRP Kidney LAG3+ Liposarcoma Liquid Biopsy liver Liver liver tissue Lung lungs Lupus Lymphocytes Lymphoma lymphoma Melanoma melanoma Mesothelioma Microenvironment miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets OBP Oral Cancer Oral cancer oral squamous cell carcinoma OSCC Osteoarthritis palbociclib PALLET PALOMA PALOMA-2 PanB Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PDX model PENELOPE-B PFAS PI3K inhibitors PIK3CA mutation PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Rbsig Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing Testicular cancer Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast CancerTNBC Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2021

Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery

Stratakis, N., et al., Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery, Environemental Health Perspectives, https://ehp.niehs.nih.gov/doi/abs/10.1289/isee.2021.O-TO-140

View External Link

Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates

Kwak, M., et al., Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates,  J Transl Med 19, 371 (2021). https://doi.org/10.1186/s12967-021-03044-5

View External Link

Antigen-experienced CXCR5- CD19low B cells are plasmablast precursors expanded in SLE

Dorner, T.,  et al. Antigen-experienced CXCR5- CD19low B cells are  plasmablast precursors expanded in SLE.  medRxiv preprint May 27, 2021 https://doi.org/10.1101/2021.05.25.21257784doi

Download pdf 11.1MB

Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma.

Bustos, M. A., et al. Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. J Clin Oncol 39, 2021 (suppl 15; abstr e16577); DOI: 10.1200/JCO.2021.39.15_suppl.e16577

View External Link

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519

View External Link

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Loibl, S., et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 506) DOI: 10.1200/JCO.2021.39.15_suppl.506

View External Link

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.

Jaramillo, M. C., et al. Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel. J Clin Oncol 39, 2021 (suppl 15; abstr e14528). DOI: 10.1200/JCO.2021.39.15_suppl.e14528

View External Link

Hyperglycemia Regulated Circulating MicroRNAs and Their Effects on Renal Function Decline in Type 2 Diabetes

Kobayashi, H., et al. Hyperglycemia Regulated Circulating MicroRNAs and Their Effects on Renal Function Decline in Type 2 Diabetes.  J Endocr Soc. 2021 May 3; 5(Suppl 1): A414. Published online 2021 May 3. doi: 10.1210/jendso/bvab048.845

View External Link

Distal mediator-enriched, placental transcriptome-wide analyses illustrate the Developmental Origins of Health and Disease

Bhattacharya, A. et al. Distal mediator-enriched, placental transcriptome-wide analyses illustrate the Developmental Origins of Health and Disease. medRxiv APR 14, 2021. doi: https://doi.org/10.1101/2021.04.12.21255170. Pre-print

Download pdf 1.9MB

Page last updated May 22, 2023